TOKYO and CAMBRIDGE, United Kingdom and GUILFORD, Conn., 6 July 2021 — Sosei Group Corporation, the world leader in GPCR-focused Structure-Based Drug Design and Development (SBDD), and InveniAI® LLC, a global leader in pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to transform innovation across drug discovery and development, announced today the initiation of a new R&D collaboration.
The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI- and ML-based approach can be applied to generate compelling evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways; the goal being to use these targets as a basis for SBDD to generate novel compounds that could improve responses to existing immunotherapies.
The collaboration will combine InveniAI's AI-powered platform, AlphaMeld®, for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities to generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.
Miles Congreve, Ph.D., Chief Scientific Officer, Sosei Heptares, said, "We are excited to work together with InveniAI and look forward to integrating our unique capabilities to seek and identify new links between undrugged GPCR targets and compelling disease indications. InveniAI's AlphaMeld® platform will deconvolute the biology of disease and industrialize target discovery by rapidly unraveling connections between GPCR targets and diseases with high unmet need."
InveniAI's Chief Business Officer, Aman Kant, added, "We are delighted to collaborate with Sosei Heptares, an industry leader in GPCR-based therapeutic modality. We have consistently demonstrated our AI capabilities in generating clinic-ready programs across various therapeutic modalities, including biologics, small molecules, and nucleotide-based therapies."